Carbidopa and Levodopa NDC 60219-2033

NDC codes

FDA NDC Directory

Product NDC (as listed)60219-2033Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60219-2033Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
60219-2033-1	60219203301	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2033-1)Marketed from Dec 21, 2022
60219-2033-3	60219203303	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2033-3)Marketed from Dec 21, 2022
60219-2033-5	60219203305	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2033-5)Marketed from Dec 21, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa and Levodopa
Generic name (nonproprietary): carbidopa and levodopa
Active ingredients: Carbidopa hydrate — 25 mg/1Levodopa — 100 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Amneal Pharmaceuticals NY LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076521
Marketing start: Dec 21, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 60219-2033_b5ad7e75-c6cd-4b2d-a3bf-e2e860d5b9c1SPL ID b5ad7e75-c6cd-4b2d-a3bf-e2e860d5b9c1SPL set ID 0eb24333-3c11-41dd-888d-3a30d3c9d188RxCUI 308988, 308989UNII 46627O600J, MNX7R8C5VOUPC 0360219203310, 0360219203419
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460219203301 followed by a unit qualifier and the quantity

Package 60219-2033-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076521

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076521
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa and Levodopa	Carbidopa hydrate 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Amneal Pharmaceuticals NY LLC	60219-2034